Primary Graft Dysfunction
16
4
4
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
2 terminated out of 16 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
Prospective Reduction Of Transplant Complications Through Enhanced Preservation Therapy to Prevent Primary Graft Dysfunction
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
Identifying Optimal PEEP After Lung Transplantation
CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation
Primary Graft Dysfunction, Pronation, Bilateral Lung Transplants
Perioperative Vitamin C Lung Transplant
Exhaled Breath Particles in Lung Transplantation
Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction
Measurement of Extravascular Lung Water to Detect and Predict Primary Graft Dysfunction Following Lung Transplant
Heart Transplant and Primary Transplant Dysfunction: a Retrospective Analysis of the Strasbourg Experience
Pneumoproteins Expression in the Organ Donor
Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation
Quantifying Physical and Biochemical Factors That Contribute to Primary Graft Dysfunction After Lung Transplantation
The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study